Vol. 1 No. 10 (2021)
Reimbursement Reviews

Venetoclax (Venclexta)

Published October 19, 2021

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses venetoclax (Venclexta), 10 mg, 50 mg, 100 mg, tablets, oral.
  • Indication: Venclexta, in combination with azacitidine or low-dose cytarabine is indicated for the treatment of patients with newly diagnosed AML who are 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy.